Skip to main content
Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

< Back to Article

Figure 1.

Study Flow.

Notes: 1792 of 3317 screened individuals were eligible to participate in the study. The most common reasons for exclusion were living more than a 30-minute drive from the ACT vendor and not having a mobile phone, followed by purchasing drugs for somebody who was not a member of the same household. Of those eligible for study participation, 1140 enrolled with the same mobile phone number that they shared with data enumerators, of whom 554 were randomized to the control group, 277 to the reminder-only message group, and 309 to the reminder and additional information message group. A total of 1110 participants reported on their ACT adherence and were included in the main analysis.

More »

Figure 1 Expand

Table 1.

Sample Characteristics.

More »

Table 1 Expand

Figure 2.

Dose completion among adults in the control group.

Notes: Figure 2 indicates the proportion of adults in the control group who reported taking each dose of treatment in the per-dose self-report. Among 239 adults who took AL and reported per-dose adherence, 200 (83.7%) reported taking the fourth dose, 174 (72.8%) reported taking the fifth dose, and 135 (56.5%) reported taking the sixth dose. Among 70 adults in the control group taking AS+AQ, 33 (47.9%) reported completing the full three-dose regimen.

More »

Figure 2 Expand

Table 2.

Effect of text message treatment on self-reported adherence.

More »

Table 2 Expand

Table 3.

Per-protocol Subgroup Analysis.

More »

Table 3 Expand

Table 4.

Self-reported treatment completion and remaining pills or ACT Stock.

More »

Table 4 Expand

Table 5.

Effect of treatment on still feeling sick.

More »

Table 5 Expand